The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Chemotherapy-free immunotherapy-based treatment approaches for NSCLC
Jarushka Naidoo, MD, John Hopkins University, Baltimore, MD, discusses chemotherapy-free immunotherapy-based approaches in non-small cell lung cancer (NSCLC). Patients with PD-L1-high NSCLC have the chemotherapy-free option of pembrolizumab monotherapy. In regards to combination immunotherapy, Dr Naidoo highlights the regimen investigated in the Phase III CheckMate 227 (NCT02477826) trial of nivolumab plus ipilimumab in patients with advanced NSCLC and additionally emphasizes the requirement of biomarker discovery to further refine which patients benefit from IO alone. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
